multiple sclerosis

Summary

Summary: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)

Top Publications

  1. ncbi Immunology of multiple sclerosis
    Mireia Sospedra
    Cellular Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 1400, USA
    Annu Rev Immunol 23:683-747. 2005
  2. ncbi No cerebrocervical venous congestion in patients with multiple sclerosis
    Florian Doepp
    Department of Neurology, University Hospital Charite, Humboldt University, Berlin, Germany
    Ann Neurol 68:173-83. 2010
  3. ncbi Venous and cerebrospinal fluid flow in multiple sclerosis: a case-control study
    Peter Sundström
    Department of Clinical Neuroscience, Umea University, Sweden
    Ann Neurol 68:255-9. 2010
  4. pmc Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
    Chris H Polman
    Department of Neurology, Free University, Amsterdam, The Netherlands
    Ann Neurol 69:292-302. 2011
  5. ncbi Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"
    Chris H Polman
    VU Medical Center Amsterdam, Free University, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Neurol 58:840-6. 2005
  6. ncbi Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis
    W I McDonald
    Royal College of Physicians, London, United Kingdom
    Ann Neurol 50:121-7. 2001
  7. ncbi Multiple sclerosis
    Alastair Compston
    Department of Clinical Neurosciences, University of Cambridge Clinical School, Addenbrooke s Hospital, Cambridge, UK
    Lancet 372:1502-17. 2008
  8. ncbi Revised diagnostic criteria for neuromyelitis optica
    D M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Neurology 66:1485-9. 2006
  9. pmc Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
    Cris S Constantinescu
    Division of Clinical Neurology, School of Clinical Sciences, University of Nottingham, Queen s Medical Centre, Nottingham, UK
    Br J Pharmacol 164:1079-106. 2011
  10. ncbi Improving the translational hit of experimental treatments in multiple sclerosis
    Hanna M Vesterinen
    Centre for Clinical Brain Sciences, Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, UK
    Mult Scler 16:1044-55. 2010

Research Grants

Detail Information

Publications353 found, 100 shown here

  1. ncbi Immunology of multiple sclerosis
    Mireia Sospedra
    Cellular Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 1400, USA
    Annu Rev Immunol 23:683-747. 2005
    b>Multiple sclerosis (MS) develops in young adults with a complex predisposing genetic trait and probably requires an inciting environmental insult such as a viral infection to trigger the disease...
  2. ncbi No cerebrocervical venous congestion in patients with multiple sclerosis
    Florian Doepp
    Department of Neurology, University Hospital Charite, Humboldt University, Berlin, Germany
    Ann Neurol 68:173-83. 2010
    b>Multiple sclerosis (MS) is characterized by demyelination centered around cerebral veins...
  3. ncbi Venous and cerebrospinal fluid flow in multiple sclerosis: a case-control study
    Peter Sundström
    Department of Clinical Neuroscience, Umea University, Sweden
    Ann Neurol 68:255-9. 2010
    The prevailing view on multiple sclerosis etiopathogenesis has been challenged by the suggested new entity chronic cerebrospinal venous insufficiency...
  4. pmc Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
    Chris H Polman
    Department of Neurology, Free University, Amsterdam, The Netherlands
    Ann Neurol 69:292-302. 2011
    New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The use of imaging for demonstration of dissemination of central nervous system lesions in space and time has been ..
  5. ncbi Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"
    Chris H Polman
    VU Medical Center Amsterdam, Free University, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Neurol 58:840-6. 2005
    New diagnostic criteria for multiple sclerosis integrating magnetic resonance image assessment with clinical and other paraclinical methods were introduced in 2001...
  6. ncbi Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis
    W I McDonald
    Royal College of Physicians, London, United Kingdom
    Ann Neurol 50:121-7. 2001
    The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on the objective demonstration of dissemination of lesions in both time and space...
  7. ncbi Multiple sclerosis
    Alastair Compston
    Department of Clinical Neurosciences, University of Cambridge Clinical School, Addenbrooke s Hospital, Cambridge, UK
    Lancet 372:1502-17. 2008
    b>Multiple sclerosis is primarily an inflammatory disorder of the brain and spinal cord in which focal lymphocytic infiltration leads to damage of myelin and axons...
  8. ncbi Revised diagnostic criteria for neuromyelitis optica
    D M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Neurology 66:1485-9. 2006
    ..proposed diagnostic criteria for neuromyelitis optica (NMO) that facilitate its distinction from prototypic multiple sclerosis (MS)...
  9. pmc Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
    Cris S Constantinescu
    Division of Clinical Neurology, School of Clinical Sciences, University of Nottingham, Queen s Medical Centre, Nottingham, UK
    Br J Pharmacol 164:1079-106. 2011
    ..EAE) is the most commonly used experimental model for the human inflammatory demyelinating disease, multiple sclerosis (MS)...
  10. ncbi Improving the translational hit of experimental treatments in multiple sclerosis
    Hanna M Vesterinen
    Centre for Clinical Brain Sciences, Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, UK
    Mult Scler 16:1044-55. 2010
    ..In other neurological diseases, the failure to translate pre-clinical findings to effective clinical treatments has been partially attributed to bias introduced by shortcomings in the design of animal experiments...
  11. ncbi A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
    Vanda A Lennon
    Department of Neurology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Lancet 364:2106-12. 2004
    ..It is commonly misdiagnosed as multiple sclerosis. Neither disease has a distinguishing biomarker, but optimum treatments differ...
  12. ncbi Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis
    F D Lublin
    Department of Neurology, Jefferson Medical College, Philadelphia, PA, USA
    Neurology 46:907-11. 1996
    ..In this report, we provide a summary of the survey results and propose standardized definitions for the most common clinical courses of patients with MS...
  13. ncbi Rare variants in the CYP27B1 gene are associated with multiple sclerosis
    Sreeram V Ramagopalan
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Ann Neurol 70:881-6. 2011
    b>Multiple sclerosis (MS) is a complex neurological disease...
  14. pmc Inflammatory cortical demyelination in early multiple sclerosis
    Claudia F Lucchinetti
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    N Engl J Med 365:2188-97. 2011
    Cortical disease has emerged as a critical aspect of the pathogenesis of multiple sclerosis, being associated with disease progression and cognitive impairment...
  15. pmc Oxidative damage in multiple sclerosis lesions
    Lukas Haider
    Centre for Brain Research, Medical University of Vienna, A 1090 Vienna, Austria
    Brain 134:1914-24. 2011
    b>Multiple sclerosis is a chronic inflammatory disease of the central nervous system, associated with demyelination and neurodegeneration...
  16. pmc Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis
    John S Tzartos
    Department of Neuropathology, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
    Am J Pathol 172:146-55. 2008
    Recent findings in the animal model for multiple sclerosis (MS), experimental autoimmune encephalomyelitis, implicate a novel CD4+ T-cell subset (TH17), characterized by the secretion of interleukin-17 (IL-17), in disease pathogenesis...
  17. ncbi Multiple sclerosis--the plaque and its pathogenesis
    Elliot M Frohman
    Department of Neurology and Ophthalmology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
    N Engl J Med 354:942-55. 2006
  18. ncbi Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis
    Sergio E Baranzini
    Department of Neurology, University of California, San Francisco, CA 94143 0435, USA
    Hum Mol Genet 18:767-78. 2009
    b>Multiple sclerosis (MS), a chronic disorder of the central nervous system and common cause of neurological disability in young adults, is characterized by moderate but complex risk heritability...
  19. pmc Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis
    P Zamboni
    Vascular Diseases Center, University of Ferrara, Ferrara, Italy
    J Neurol Neurosurg Psychiatry 80:392-9. 2009
    The extracranial venous outflow routes in clinically defined multiple sclerosis (CDMS) have not previously been investigated.
  20. ncbi Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
    Volker Brinkmann
    Department of Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Campus Forum 1, WSJ 386, CH 4056 Basel, Switzerland
    Nat Rev Drug Discov 9:883-97. 2010
    ..Novartis), an orally active immunomodulatory drug, has opened up new approaches to the treatment of multiple sclerosis, the most common inflammatory disorder of the central nervous system...
  21. pmc Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci
    Nikolaos A Patsopoulos
    Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Ann Neurol 70:897-912. 2011
    To perform a 1-stage meta-analysis of genome-wide association studies (GWAS) of multiple sclerosis (MS) susceptibility and to explore functional consequences of new susceptibility loci.
  22. ncbi A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis
    Ivana Nikic
    Research Unit Therapy Development, Institute of Clinical Neuroimmunology, Ludwig Maximilians Universitat Munchen, Munich, Germany
    Nat Med 17:495-9. 2011
    In multiple sclerosis, a common inflammatory disease of the central nervous system, immune-mediated axon damage is responsible for permanent neurological deficits. How axon damage is initiated is not known...
  23. pmc Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models
    Lianhua Bai
    Center for Translational Neuroscience, Department of Neurosciences, Case School of Medicine, Case Western Reserve University, Cleveland, OH, USA
    Nat Neurosci 15:862-70. 2012
    ..In animal models of multiple sclerosis, an autoimmune disease that targets oligodendrocytes and myelin, treatment with human MSCs results in ..
  24. pmc Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis
    Dimitrios Karussis
    Department of Neurology, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem IL 91120, Israel
    Arch Neurol 67:1187-94. 2010
    ..and immunological effects of intrathecal and intravenous administration of autologous mesenchymal stem cells (MSCs) (also called mesenchymal stromal cells) in patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).
  25. pmc Pathway and network-based analysis of genome-wide association studies in multiple sclerosis
    Sergio E Baranzini
    Department of Neurology, School of Medicine, University of California San Francisco, 513 Parnassus Ave Room S 256, San Francisco, CA 94143 0435, USA
    Hum Mol Genet 18:2078-90. 2009
    Genome-wide association studies (GWAS) testing several hundred thousand SNPs have been performed in multiple sclerosis (MS) and other complex diseases...
  26. ncbi Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity
    Diego Centonze
    Department of Neuroscience, University Hospital Tor Vergata, Rome, Italy
    Ann Neurol 70:51-8. 2011
    It is still unclear whether chronic cerebrospinal venous insufficiency (CCSVI) is associated with multiple sclerosis (MS), because substantial methodological differences have been claimed by Zamboni to account for the lack of results of ..
  27. ncbi Multiple sclerosis
    Alastair Compston
    Neurology Unit, University of Cambridge Clinical School, Addenbrooke s Hospital, Cambridge CB2 2QQ, UK
    Lancet 359:1221-31. 2002
    b>Multiple sclerosis is the prototype inflammatory autoimmune disorder of the central nervous system and, with a lifetime risk of one in 400, potentially the most common cause of neurological disability in young adults...
  28. ncbi C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE
    Andrea Reboldi
    Institute for Research in Biomedicine, Bellinzona, Switzerland
    Nat Immunol 10:514-23. 2009
    ..Our results identify distinct molecular requirements and ports of lymphocyte entry into uninflamed versus inflamed CNS and suggest that the CCR6-CCL20 axis in the choroid plexus controls immune surveillance of the CNS...
  29. ncbi Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis
    Shanu F Roemer
    Department of Neurology, Mayo Clinic, College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Brain 130:1194-205. 2007
    ..Its pathogenic relationship to multiple sclerosis (MS) is uncertain...
  30. pmc T cells in multiple sclerosis and experimental autoimmune encephalomyelitis
    J M Fletcher
    Immune Regulation Research Group, School of Biochemistry and Immunology, Trinity College, St Vincent s University Hospital, Dublin, Ireland
    Clin Exp Immunol 162:1-11. 2010
    b>Multiple sclerosis (MS) is a demyelinating inflammatory disorder of the central nervous system (CNS), which involves autoimmune responses to myelin antigens...
  31. ncbi Cortical demyelination and diffuse white matter injury in multiple sclerosis
    Alexandra Kutzelnigg
    Center for Brain Research, Medical University of Vienna, Vienna, Austria
    Brain 128:2705-12. 2005
    Focal demyelinated plaques in white matter, which are the hallmark of multiple sclerosis pathology, only partially explain the patient's clinical deficits...
  32. pmc Multiple sclerosis
    Alyssa Nylander
    Department of Neurology and Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut 06520, USA
    J Clin Invest 122:1180-8. 2012
    b>Multiple sclerosis (MS) is a multifocal demyelinating disease with progressive neurodegeneration caused by an autoimmune response to self-antigens in a genetically susceptible individual...
  33. ncbi Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
    Ralf A Linker
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, D 44791 Bochum, Germany
    Brain 134:678-92. 2011
    Inflammation and oxidative stress are thought to promote tissue damage in multiple sclerosis. Thus, novel therapeutics enhancing cellular resistance to free radicals could prove useful for multiple sclerosis treatment...
  34. ncbi Will the real multiple sclerosis please stand up?
    Peter K Stys
    Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    Nat Rev Neurosci 13:507-14. 2012
    b>Multiple sclerosis (MS) is considered to be an autoimmune, inflammatory disease of the CNS. In most patients, the disease follows a relapsing-remitting course and is characterized by dynamic inflammatory demyelinating lesions in the CNS...
  35. ncbi Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity
    R H S R Roxburgh
    Neurology Department, Cambridge University, UK
    Neurology 64:1144-51. 2005
    There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease.
  36. pmc Expression of HERV-Fc1, a human endogenous retrovirus, is increased in patients with active multiple sclerosis
    Magdalena Janina Laska
    Department of Biomedicine, Aarhus University, Aarhus, Denmark
    J Virol 86:3713-22. 2012
    b>Multiple sclerosis (MS) is considered to be an autoimmune disease with an unknown cause and with immune system dysregulation. Among environmental factors, viruses are most often connected with the etiology of MS...
  37. ncbi The genetics of multiple sclerosis: an up-to-date review
    Pierre Antoine Gourraud
    Department of Neurology, University of California San Francisco, San Francisco, CA 94143 0435, USA
    Immunol Rev 248:87-103. 2012
    b>Multiple sclerosis (MS) is a prevalent inflammatory disease of the central nervous system that often leads to disability in young adults. Treatment options are limited and often only partly effective...
  38. ncbi Multiple sclerosis: an immune or neurodegenerative disorder?
    Bruce D Trapp
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Annu Rev Neurosci 31:247-69. 2008
    b>Multiple sclerosis (MS) is an inflammatory-mediated demyelinating disease of the human central nervous system...
  39. pmc Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis
    S Hong Lee
    The University of Queensland, Queensland Brain Institute, Brisbane, QLD 4072, Australia
    Hum Mol Genet 22:832-41. 2013
    Common diseases such as endometriosis (ED), Alzheimer's disease (AD) and multiple sclerosis (MS) account for a significant proportion of the health care burden in many countries...
  40. pmc C3-dependent mechanism of microglial priming relevant to multiple sclerosis
    Valeria Ramaglia
    Department of Infection, Immunity, and Biochemistry, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom
    Proc Natl Acad Sci U S A 109:965-70. 2012
    ..Relevance for neurodegenerative disease is exemplified by human multiple sclerosis (MS) and by experimental autoimmune encephalomyelitis (EAE), a model of MS...
  41. ncbi Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
    Owain W Howell
    Centre for Neuroscience, Division of Experimental Medicine, Imperial College Faculty of Medicine, Hammersmith Hospital Campus, Burlington Danes Building, Du Cane Road, London W12 0NN, UK
    Brain 134:2755-71. 2011
    ..has been suggested to play a prominent role in the development of cerebral cortical grey matter pathology in multiple sclerosis. The aim of this study was to analyse the incidence and distribution of B cell follicle-like structures in ..
  42. ncbi Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms
    Judith M Greer
    The University of Queensland, UQ Centre for Clinical Research, Royal Brisbane and Women s Hospital, Brisbane, 4029, Australia
    J Neuroimmunol 234:7-18. 2011
    b>Multiple sclerosis (MS) is more prevalent in females than males, and this female predominance is increasing as time goes by...
  43. pmc Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)
    Paul Wicks
    PatientsLikeMe, Research and Development, Cambridge, MA 02141, USA
    J Med Internet Res 13:e12. 2011
    Patients with multiple sclerosis (MS) may face barriers, such as treatment fatigue, memory problems, or side effects, that may influence their adherence to medication.
  44. ncbi Potassium channel KIR4.1 as an immune target in multiple sclerosis
    Rajneesh Srivastava
    Department of Neurology, Klinikum rechts der Isar, Technische Universitat, Munich, Germany
    N Engl J Med 367:115-23. 2012
    b>Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system. Many findings suggest that the disease has an autoimmune pathogenesis; the target of the immune response is not yet known.
  45. pmc Autoimmune T cell responses in the central nervous system
    Joan Goverman
    Department of Immunology, University of Washington, Seattle, Washington 98195 7650, USA
    Nat Rev Immunol 9:393-407. 2009
    Autoreactive T cell responses have a crucial role in central nervous system (CNS) diseases such as multiple sclerosis. Recent data indicate that CNS autoimmunity can be mediated by two distinct lineages of CD4+ T cells that are defined by ..
  46. pmc FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation
    Ji Woong Choi
    Department of Molecular Biology, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 108:751-6. 2011
    Sphingosine 1-phosphate (S1P), a lysophospholipid, has gained relevance to multiple sclerosis through the discovery of FTY720 (fingolimod), recently approved as an oral treatment for relapsing forms of multiple sclerosis...
  47. ncbi Environmental risk factors for multiple sclerosis. Part I: the role of infection
    Alberto Ascherio
    Department of Nutrition, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Ann Neurol 61:288-99. 2007
    Although genetic susceptibility explains the clustering of multiple sclerosis (MS) cases within families and the sharp decline in risk with increasing genetic distance, it cannot fully explain the geographic variations in MS frequency and ..
  48. pmc NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury
    Marie T Fischer
    Centre for Brain Research, Medical University of Vienna, A 1090 Wien, Austria
    Brain 135:886-99. 2012
    b>Multiple sclerosis is a chronic inflammatory disease of the central nervous system, associated with demyelination and neurodegeneration...
  49. ncbi The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy
    Yossi Gilgun-Sherki
    Laboratory of Neurosciences, Felsenstein Medical Research Center, The Sackler School of Medicine, Tel Aviv University, Petach Tikva 49100, Israel
    J Neurol 251:261-8. 2004
    Accumulating data indicate that oxidative stress (OS) plays a major role in the pathogenesis of multiple sclerosis (MS)...
  50. pmc Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record
    Marylyn D Ritchie
    Center for Human Genetics Research, Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Am J Hum Genet 86:560-72. 2010
    ..Twenty-one SNPs previously implicated as common variants predisposing to atrial fibrillation, Crohn disease, multiple sclerosis, rheumatoid arthritis, or type 2 diabetes were successfully genotyped in 9483 samples accrued over 4 mo into ..
  51. pmc The perfect crime? CCSVI not leaving a trace in MS
    Christoph A Mayer
    Department of Neurology, Goethe University Frankfurt, Schleusenweg 2 16, 60528 Frankfurt am Main, Germany
    J Neurol Neurosurg Psychiatry 82:436-40. 2011
    b>Multiple sclerosis (MS) is a chronic, inflammatory demyelinating disease of the central nervous system, believed to be triggered by an autoimmune reaction to myelin...
  52. ncbi Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration
    Joanna Mikita
    University Victor Segalen, France
    Mult Scler 17:2-15. 2011
    ..M1 and immunomodulatory M2 activation profiles of circulating monocytes in relapsing experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis, and tested whether altered M1/M2 equilibrium promotes CNS inflammation.
  53. ncbi Gray matter atrophy in multiple sclerosis: a longitudinal study
    Elizabeth Fisher
    Department of Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Ann Neurol 64:255-65. 2008
    To determine gray matter (GM) atrophy rates in multiple sclerosis (MS) patients at all stages of disease, and to identify predictors and clinical correlates of GM atrophy.
  54. ncbi The changing demographic pattern of multiple sclerosis epidemiology
    Nils Koch-Henriksen
    Department of Neurology, Aarhus University Hospital in Aalborg, Aalborg, Denmark
    Lancet Neurol 9:520-32. 2010
    The uneven distribution of multiple sclerosis (MS) across populations can be attributed to differences in genes and the environment and their interaction...
  55. ncbi Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research
    Ralf Gold
    Institute for Multiple Sclerosis Research, Department of Experimental and Clinical Neuroimmunology, University of Goettingen and Gemeinnützige Hertie Stiftung, Gottingen, Germany
    Brain 129:1953-71. 2006
    In view of disease heterogeneity of multiple sclerosis and limited access to ex vivo specimens, different approaches must be undertaken to better understand disease pathogenesis and new therapeutic challenges...
  56. pmc Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis
    Serena Sanna
    Istituto di Neurogenetica e Neurofarmacologia, Consiglio Nazionale delle Ricerche, Monserrato, Italy
    Nat Genet 42:495-7. 2010
    ..6 million genotyped or imputed variants in 882 Sardinian individuals with multiple sclerosis (cases) and 872 controls suggested association of CBLB gene variants with disease, which was confirmed in 1,..
  57. ncbi Diffusion tensor-MRI evidence for extra-axonal neuronal degeneration in caudate and thalamic nuclei of patients with multiple sclerosis
    S Hannoun
    CREATIS, UMR 5220 CNRS and U1044 INSERM, Universite Claude Bernard Lyon1, University of Lyon, France
    AJNR Am J Neuroradiol 33:1363-8. 2012
    ..The relationship between diffusivity markers, and atrophy of the caudate and the thalamus, as well as brain lesion load and clinical status of the patients was also explored...
  58. ncbi Oligodendrocytes and the early multiple sclerosis lesion
    John W Prineas
    Institute of Clinical Neurosciences, Department of Medicine, University of Sydney, Camperdown, Australia
    Ann Neurol 72:18-31. 2012
    There is little agreement among neuropathologists regarding the timing and nature of oligodendrocyte loss in multiple sclerosis (MS). This review describes changes that accompany acute oligodendrocyte loss in new lesions...
  59. pmc Temporal trends in the incidence of multiple sclerosis: a systematic review
    Alvaro Alonso
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, West Bank Office Building, 1300 S 2nd St, Suite 300, Minneapolis, MN 55454, USA
    Neurology 71:129-35. 2008
    b>Multiple sclerosis (MS) has been traditionally considered to be more frequent in women and in regions more distant from the equator...
  60. pmc B cells in multiple sclerosis: connecting the dots
    H Christian von Büdingen
    Department of Neurology, University of California San Francisco, San Francisco, CA 94143, USA
    Curr Opin Immunol 23:713-20. 2011
    Over the past two decades B cells have increasingly moved into the spotlight in multiple sclerosis (MS) research...
  61. ncbi Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation
    Hania Kebir
    Neuroimmunology Unit, Center for the Study of Brain Diseases, Centre Hospitalier de l Université de Montréal Notre Dame Hospital, 1560 Sherbrooke Street East, Montreal, Quebec H2L 4M1, Canada
    Nat Med 13:1173-5. 2007
    ..here the expression of IL-17 and IL-22 receptors on blood-brain barrier endothelial cells (BBB-ECs) in multiple sclerosis lesions, and show that IL-17 and IL-22 disrupt BBB tight junctions in vitro and in vivo...
  62. ncbi High nationwide prevalence of multiple sclerosis in Sweden
    C Ahlgren
    Department of Neurology, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden
    Mult Scler 17:901-8. 2011
    Few nationwide multiple sclerosis (MS) prevalence studies have been published. In Scandinavia, the nationwide MS prevalence was 173/100,000 in Denmark 2005 and 100/100,000 in Iceland 1990.
  63. pmc A comparison of health utility measures for the evaluation of multiple sclerosis treatments
    J D Fisk
    Abbie J Lane Building, Queen Elizabeth II Health Sciences Centre, Veterans Memorial Lane, Halifax, Nova Scotia B3H 2E3, Canada
    J Neurol Neurosurg Psychiatry 76:58-63. 2005
    ..To evaluate the practical application and psychometric properties of three health utility measures in a sample of MS patients with a broad range of neurological disability as measured by the Extended Disability Status Scale (EDSS)...
  64. ncbi MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis
    Changsheng Du
    Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
    Nat Immunol 10:1252-9. 2009
    ..T(H)-17 cells) are increasingly recognized as key participants in various autoimmune diseases, including multiple sclerosis. Although sets of transcription factors and cytokines are known to regulate T(H)-17 differentiation, the ..
  65. ncbi Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
    Ludwig Kappos
    University Hospital, Basel, Switzerland
    Lancet Neurol 8:987-97. 2009
    The Betaferon/Betaseron in newly emerging multiple sclerosis for initial treatment (BENEFIT) trial investigated the effect of treatment with interferon beta-1b after a clinically isolated syndrome...
  66. ncbi Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
    M Mehling
    Department of Neurology, University Hospitals Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    Neurology 75:403-10. 2010
    ..S1P) receptor modulator that showed efficacy in phase II and III clinical trials in patients with multiple sclerosis (MS)...
  67. ncbi Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story
    Ana Caminero
    Seccion de Neurologia, Complejo Hospitalario de Avila, Spain
    J Neuroimmunol 234:1-6. 2011
    ..TNF-α is involved in the pathogenesis of multiple sclerosis (MS), however, administration of anti-TNF-α agents to MS patients has been associated with increased ..
  68. ncbi Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis
    T Misu
    Department of Neurology, Tohoku University School of Medicine, 1 1 Seiryomachi, Aobaku, Sendai 980 8574, Japan
    Brain 130:1224-34. 2007
    ..There has been a long controversy as to whether NMO is a variant of multiple sclerosis (MS) or a distinct disease...
  69. ncbi No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset
    Claudio Baracchini
    First Neurology Clinic, University Hospital, Padova, Italy
    Ann Neurol 69:90-9. 2011
    ..cerebrospinal venous insufficiency (CCSVI), has been recently hypothesized to be the possible cause of multiple sclerosis (MS)...
  70. ncbi CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system
    Alexander Mildner
    Department of Neuropathology, University of Freiburg, Freiburg, Germany
    Brain 132:2487-500. 2009
    ..Collectively, these data indicate a disease-promoting role of CCR2+Ly-6Chi monocytes during autoimmune inflammation of the central nervous system...
  71. ncbi Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain
    Klaus Schmierer
    Department of Neuroinflammation, MS NMR Research Unit, University College London, United Kingdom
    Ann Neurol 56:407-15. 2004
    Several quantitative magnetic resonance (MR) measures are used to investigate multiple sclerosis (MS) in vivo. Precise quantitative investigation of the histopathological correlates of such measures has, to date, been limited...
  72. ncbi Multiple sclerosis: a complicated picture of autoimmunity
    Henry F McFarland
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Immunol 8:913-9. 2007
    Understanding of autoimmune diseases, including multiple sclerosis, has expanded considerably in recent years...
  73. pmc Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis
    Jerold Chun
    Department of Molecular Biology, Helen L Dorris Child and Adolescent Neuropsychiatric Disorder Institute, The Scripps Research Institute, La Jolla, CA, USA
    Clin Neuropharmacol 33:91-101. 2010
    ..orally bioavailable compound that has shown efficacy in advanced clinical trials for the treatment of multiple sclerosis (MS)...
  74. ncbi MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47
    Andreas Junker
    Institute for Clinical Neuroimmunology, Ludwig Maximilians University, Munich, Germany
    Brain 132:3342-52. 2009
    We established microRNA profiles from active and inactive multiple sclerosis lesions...
  75. ncbi Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis
    Barbara Serafini
    Department of Cell Biology and Neuroscience, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Roma, Italy
    Brain Pathol 14:164-74. 2004
    b>Multiple sclerosis (MS) is characterized by synthesis of oligoclonal immunoglobulins and the presence of B-cell clonal expansions in the central nervous system (CNS)...
  76. pmc Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla
    Francesca Bagnato
    National Institutes of Neurological Disorders and Stroke NINDS, National Institutes of Health, Bethesda, MD, USA
    Brain 134:3602-15. 2011
    ..In multiple sclerosis, iron accumulation in brain tissue may reflect a multiplicity of pathological processes...
  77. pmc Association of retinal and macular damage with brain atrophy in multiple sclerosis
    Jan Dorr
    NeuroCure Clinical Research Center, Charite Universitaetsmedizin Berlin, Berlin, Germany
    PLoS ONE 6:e18132. 2011
    ..degeneration in the central nervous system contributes substantially to the long term disability in multiple sclerosis (MS) patients. However, in vivo determination and monitoring of neurodegeneration remain difficult...
  78. ncbi Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability
    Stefan D Roosendaal
    Department of Radiology, VU University Medical Centre, Amsterdam, The Netherlands
    Mult Scler 17:1098-106. 2011
    Although grey matter damage in multiple sclerosis is currently recognized, determinants of grey matter volume and its relationship with disability are not yet clear.
  79. pmc Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria
    Hans Lassmann
    Centre for Brain Research, Medical University of Vienna, Spitalgasse 4, A 1090 Wien, Austria
    Brain 134:2772-86. 2011
    ..and immunological studies provide evidence for an association between Epstein-Barr virus infection and multiple sclerosis, suggesting a role of Epstein-Barr virus infection in disease induction and pathogenesis...
  80. ncbi Extracranial venous hemodynamics in multiple sclerosis: a case-control study
    G Tsivgoulis
    Kapodistriou 3, Nea Chili, Alexandroupolis, Greece
    Neurology 77:1241-5. 2011
    ..chronic cerebrospinal venous insufficiency (CCSVI), has recently been implicated in the pathogenesis of multiple sclerosis (MS)...
  81. ncbi Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
    Jeffrey A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Ann Neurol 69:759-77. 2011
    Until recently, all approved multiple sclerosis (MS) disease treatments were administered parenterally...
  82. pmc Association between chronic cerebrospinal venous insufficiency and multiple sclerosis: a meta-analysis
    Andreas Laupacis
    Keenan Research Centre, Li Ka Shing Knowledge Institute of St Michael s Hospital, Toronto, Ont
    CMAJ 183:E1203-12. 2011
    It has been proposed by Zamboni and colleagues that multiple sclerosis is caused by chronic cerebrospinal venous insufficiency, a term used to describe ultrasound-detectable abnormalities in the anatomy and flow of intra- and ..
  83. ncbi Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran
    Masoud Etemadifar
    Medical School, Isfahan University of Medical Sciences, Isfahan, Iran
    Mult Scler 17:1022-7. 2011
    The epidemiology of multiple sclerosis (MS) has changed in recent decades.
  84. pmc Chronic cerebrospinal venous insufficiency in multiple sclerosis: clinical correlates from a multicentre study
    Stefano Bastianello
    Department of Public Health and Neurosciences, IRCCS C, Mondino National Institute of Neurology Foundation, University of Pavia, Italy
    BMC Neurol 11:132. 2011
    Chronic cerebrospinal venous insufficiency (CCSVI) has recently been reported to be associated with multiple sclerosis (MS)...
  85. ncbi CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis
    Jean M Fletcher
    School of Biochemistry and Immunology, Trinity College, Dublin, Ireland
    J Immunol 183:7602-10. 2009
    ..An examination of T cells from multiple sclerosis patients revealed a normal frequency of CD4(+)CD25(+)CD127(low)FoxP3(+), but interestingly a deficit in the ..
  86. pmc The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability
    Antonio Scalfari
    Imperial College, Division of Neuroscience, London, UK
    Brain 133:1914-29. 2010
    The relationship of relapses to long-term disability in multiple sclerosis is uncertain. Relapse reduction is a common therapeutic target but clinical trials have shown dissociation between relapse suppression and disability accumulation...
  87. pmc Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology
    Junwei Hao
    Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China
    J Exp Med 207:1907-21. 2010
    ..We show in a mouse model of multiple sclerosis that NK cell enrichment results in disease amelioration, whereas selective blockade of NK cell homing to the ..
  88. ncbi Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
    David B Clifford
    Department of Neurology, Washington University in St Louis, Saint Louis, MO 63110, USA
    Lancet Neurol 9:438-46. 2010
    Treatment of multiple sclerosis with natalizumab is complicated by rare occurrence of progressive multifocal leukoencephalopathy (PML)...
  89. ncbi Preactive lesions in multiple sclerosis
    Paul van der Valk
    Department of Pathology, VU Medical Center, Amsterdam, The Netherlands
    Curr Opin Neurol 22:207-13. 2009
    Knowledge of the early pathological changes observed in multiple sclerosis (MS) has advanced by implementation of many improved pathological, biochemical and imaging techniques...
  90. ncbi The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure
    J Hobart
    Neurological Outcome Measures Unit, Institute of Neurology, London, UK
    Brain 124:962-73. 2001
    ..As patient-based outcome measurement is particularly important in treatment trials of multiple sclerosis, a number of disease-specific instruments have been developed recently...
  91. ncbi Blood-brain barrier disruption in multiple sclerosis
    Alireza Minagar
    Department of Neurology, Louisiana State University Health Sciences Center, Shreveport, LA 71130, USA
    Mult Scler 9:540-9. 2003
    ..migration of activated leukocytes are among the earliest cerebrovascular abnormalities seen in multiple sclerosis (MS) brains and parallel the release of inflammatory cytokines/chemokines...
  92. ncbi Altered miRNA expression in T regulatory cells in course of multiple sclerosis
    Giuseppe De Santis
    Section of Neurology, Department of Medical and Surgical Sciences of the Communication and Behaviour, University of Ferrara, Ferrara, Italy
    J Neuroimmunol 226:165-71. 2010
    b>Multiple sclerosis (MS) is a chronic inflammatory response against constituents of the central nervous system...
  93. ncbi Anomalous venous blood flow and iron deposition in multiple sclerosis
    Ajay Vikram Singh
    Department of Physics, European School of Molecular Medicine SEMM, IFOM IEO Campus, Centro Interdisciplinare Materiali e Interfacce Nanostrutturati, University of Milan, Milan, Italy
    J Cereb Blood Flow Metab 29:1867-78. 2009
    b>Multiple sclerosis (MS) is primarily an autoimmune disorder of unknown origin. This review focuses iron overload and oxidative stress as surrounding cause that leads to immunomodulation in chronic MS...
  94. ncbi Factors that influence adherence with disease-modifying therapy in MS
    Katherine Treadaway
    Dept of Neurology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75235, USA
    J Neurol 256:568-76. 2009
    ..The aim of this investigation was to identify which factors most influenced nonadherent behavior with the available disease-modifying injection therapies for multiple sclerosis (MS).
  95. pmc Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis
    Sergio E Baranzini
    Department of Neurology, University of California at San Francisco, San Francisco, California 94143, USA
    Nature 464:1351-6. 2010
    ..In multiple sclerosis (MS), an autoimmune demyelinating disease and common cause of neurodegeneration and disability in young ..
  96. ncbi Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models
    Hans Lassmann
    Centre for Brain Research, Medical University of Vienna, Spitalgasse 4, A 1090 Wien, Austria
    Exp Neurol 225:2-8. 2010
    Axonal and neuronal injury and loss are of critical importance for permanent clinical disability in multiple sclerosis patients. Axonal injury occurs already early during the disease and accumulates with disease progression...
  97. pmc Role of the innate immune system in the pathogenesis of multiple sclerosis
    Roopali Gandhi
    Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Neuroimmunol 221:7-14. 2010
    b>Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease with heterogeneous clinical presentations and course...
  98. pmc Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk
    K C Simon
    Departments of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Neurology 74:1365-71. 2010
    To examine the interplay between smoking, serum antibody titers to the Epstein-Barr virus nuclear antigens (anti-EBNA), and HLA-DR15 on multiple sclerosis (MS) risk.
  99. pmc Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score
    Philip L De Jager
    Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet Neurol 8:1111-9. 2009
    Prediction of susceptibility to multiple sclerosis (MS) might have important clinical applications, either as part of a diagnostic algorithm or as a means to identify high-risk individuals for prospective studies...
  100. pmc Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis
    Lauren S Talman
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Ann Neurol 67:749-60. 2010
    ..of optical coherence tomography (OCT) show that retinal nerve fiber layer (RNFL) thickness is reduced in multiple sclerosis (MS) and correlates with visual function...
  101. ncbi Development of biomarkers in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, NINDS, National Institutes of Health, Bldg 10, Room 5B 16, 10 Center DR MSC 1400, Bethesda, MD 20892 1400, USA
    Brain 127:1463-78. 2004
    b>Multiple sclerosis is a complex disease, as several pathophysiological processes (including inflammation, demyelination, axonal damage and repair mechanisms) participate in the disease process...

Research Grants80

  1. Immune Regulation of Bone Homeostasis
    MERVYN NEALE WEITZMANN; Fiscal Year: 2012
    ..conditions including Crohn's disease, psoriasis and psoriatic arthritis, systemic lupus erythematosus;multiple sclerosis;Type I Diabetes, and as anti-rejection agents following solid organ and bone marrow transplantation...
  2. H1R Signaling and Immune Deviation in EAE
    Cory Teuscher; Fiscal Year: 2013
    ..autoimmune diseases such as experimental allergic encephalomyelitis (EAE), the principal autoimmune model of multiple sclerosis (MS)...
  3. Principles of Therapy in Cerebellar Disease: Explorations in Ion Channel Mutants
    JOHN SAMUEL STAHL; Fiscal Year: 2013
    ..to) traumatic brain injury (TBI), damage during tumor resection, stroke, inflammatory diseases (such as multiple sclerosis), chemicals (including medications and alcohol), degeneration due to genetic errors, other degenerative ..
  4. T cell regulation by N-glycosylation
    Michael Demetriou; Fiscal Year: 2013
    ..interacts with an allele of CTLA-4 that reduces N-glycan number by ~50%, increasing the risk of Multiple Sclerosis (MS) and Rheumatoid Arthritis (RA) by ~2 fold...
  5. Neuroprotection and Myelin Repair Mechanisms in Multiple Sclerosis
    Inderjit Singh; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is central nervous system (CNS) inflammatory, demyelinating disease that affects individuals in their most productive ages...
  6. Oklahoma Autoimmunity Center of Excellence
    Judith A James; Fiscal Year: 2013
    ..b>Multiple sclerosis, rheumatoid arthritis, pediatric arthritis, insulin-dependent diabetes, idiopathic thrombocytopenia and ..
  7. Alpha B crystallin as a novel therapeutic for SIRS and Sepsis
    Jonathan B Rothbard; Fiscal Year: 2011
    ..family, recently has been shown to be a broad based anti-inflammatory agent effective in animal models of multiple sclerosis, rheumatoid arthritis, ischemia-reperfusion injury, and stroke...
  8. Role of CD44 in experimental Multiple Sclerosis
    Mitzi Nagarkatti; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is a neurodegenerative autoimmune disease that affects approximately one million people worldwide. There are over 28,000 veterans currently diagnosed with MS...
  9. Cre, Dre Dual Lineage Model for Calcium Imaging and Optogenetic Manipulations
    Petr Tvrdik; Fiscal Year: 2013
    ..and progression of neurological disorders including Alzheimer's disease, Parkinson's disease, multiple sclerosis, as well as obsessive compulsive disorder and schizophrenia...
  10. Novel Peptide MPO Inhibitors for Treating Atherosclerosis
    Kirkwood A Pritchard; Fiscal Year: 2012
    ..disease and inflammation in other disease states such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, inflammatory bowel disease, kidney disease, rheumatoid arthritis and chronic obstructive pulmonary disease, ..
  11. Studying the effects of vitamin D on FOXP3 and IL-17 expression in human CD4+ T c
    Insoo Kang; Fiscal Year: 2010
    ..including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type I diabetes mellitus (DM) and multiple sclerosis (MS)...
  12. Structural Basis for Chemokine Function
    Brian F Volkman; Fiscal Year: 2013
    ..SDF1 monomers and dimers to alter disease progression in animal models for human diseases including multiple sclerosis, ulcerative colitis, and metastatic cancer...
  13. Novel Macrolide Th17 Inhibitors
    Jay K Kolls; Fiscal Year: 2012
    ..Furthermore these cytokines have been implicated in autoimmune diseases such as multiple sclerosis and rheumatoid arthritis...
  14. Complex I: Role of L Subunit in Proton Translocation
    Steven B Vik; Fiscal Year: 2011
    ..in the protein subunits of Complex I are risk factors for a wide range of diseases and disorders, such as multiple sclerosis, Type 2 diabetes, and bipolar disorder...
  15. Growth Hormone Regulation of SH2B1
    Christin Carter-Su; Fiscal Year: 2013
    ..body growth and metabolism, and other SH2B1 activating ligands contribute to, prevent and/or alleviate symptoms of a variety of diseases including obesity, various cancers, diabetes, multiple sclerosis, and diseases of the immune system.
  16. Role of Sex Chromosome Complement in the CNS during Autoimmune Disease
    Sienmi Du; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Most autoimmune diseases affect more females than males. Multiple sclerosis (MS) is a putative autoimmune demyelinating disease of the central nervous system (CNS) characterized in the initial stages ..
  17. Mechanisms Regulating Reduced c-Kit-Dependent EAE Susceptibility in Male SJL Mice
    MELISSA ANN BROWN; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple sclerosis (MS), the most common inflammatory disease of the central nervous system (CNS), affects more than 2.5 million people worldwide...
  18. The voltage-gated Kv1.3 channel in psoriatic disease: A novel therapeutic target
    Siba P Raychaudhuri; Fiscal Year: 2012
    ..for TEM cell mediated autoimmune diseases by demonstrating that autoreactive T cells from patients with multiple sclerosis, type-1 diabetes and rheumatoid arthritis are predominantly Kv1.3high TEM cells and that Kv1...
  19. Prostaglandin signaling following seizures
    Jianxiong Jiang; Fiscal Year: 2013
    ..and chronic neurodegenerative disorders involving neuroinflammation with EP2 activation, including stroke, multiple sclerosis and Alzheimer's disease...
  20. Role of natural indoles in experimental autoimmune encephalomyelitis
    Mitzi Nagarkatti; Fiscal Year: 2013
    ..b>Multiple Sclerosis (MS) is one such autoimmune disease that affects ~350,000-500,000 people in the US...
  21. Sphingosine 1-phosphate receptors in vascular homeostasis and pathology
    TIMOTHY TUN HLA; Fiscal Year: 2012
    ..generation S1P receptor modulator called FTY720 is currently undergoing clinical trials (phase III) for multiple sclerosis and transplant rejection, the findings from this research program may provide critical information that is ..
  22. The Role of the Terminal Complement Pathway in ALS
    Scott R Barnum; Fiscal Year: 2013
    ..part to the recognition of immune-mediated contributions to other neurodegenerative diseases, including multiple sclerosis, Alzheimer's and Parkinson's disease...
  23. Immune Regulation of Viral Recrudescence
    Cornelia Bergmann; Fiscal Year: 2012
    ..in humans during infections associated with neurological complications and the demyelinating disease multiple sclerosis (MS)...
  24. CNS Demyelinating Autoimmunity Targeting Water Channel Complexes
    SEAN JOSEPH PITTOCK; Fiscal Year: 2013
    ..Neuromyelitis optica (NMO;aka optic spinal multiple sclerosis [MS]) is a devastating disease that disproportionally affects non-Caucasians...
  25. K-Channels in Lymphocyte Function and Autoimmunity
    GEORGE KANIANTHARA CHANDY; Fiscal Year: 2012
    ..Disease-associated autoreactive T cells in patients with multiple sclerosis (MS), type-1 diabetes mellitus (T1DM) and rheumatoid arthritis (RA) are TEM cells with elevated expression ..
  26. Autoimmunity Center of Excellence - Rochester
    R John Looney; Fiscal Year: 2013
    ..diseases we will target include systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, multiple sclerosis, and type I diabetes mellitus...
  27. Regulation of KSHV Latency
    Paul M Lieberman; Fiscal Year: 2013
    ..Additional diseases may also be associated with KSHV, including autoimmune disorders like multiple sclerosis and system lupus erythematosis...
  28. Endothelial-reactive antibodies: a diagnostic test for Susac's syndrome
    WILLIAM JAMES WALDMAN; Fiscal Year: 2011
    ..corpus callosum, lesions commonly detected by MRI in other regions of the brain may lead to misdiagnosis as multiple sclerosis (MS)...
  29. Effects of nerve demyelination on auditory synaptic functions
    Jun Hee Kim; Fiscal Year: 2012
    ..Myelin loss due to genetic mutations or autoimmune disease, as in the case of multiple sclerosis (MS) can result in increased motor neurons fatigue and nerve impulse conduction failure...
  30. REGULATION OF EAE WITH RECOMBINANT TCR LIGANDS
    Arthur A Vandenbark; Fiscal Year: 2013
    ..T cell specificities are present and may contribute to central nervous system (CNS) damage in subjects with multiple sclerosis (MS)...
  31. Combined neuroprotection and metabolic correction to treat leukodystrophies
    ERNESTO ROQUE BONGARZONE; Fiscal Year: 2013
    ..axons and neurons leads to permanent neurological deficits in several neurodegenerative disorders, including multiple sclerosis, Alzheimer disease, Parkinson disease and others...
  32. Molecular and Cellular Mechanisms of IL-17 Signaling
    Xiaoxia Li; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS)...
  33. A Targeted Preemptive Approach to Addressing Mitochondrial Toxicity of Nucleoside
    John K Buolamwini; Fiscal Year: 2013
    ..widespread as nucleoside drugs are used outside the antiviral and anticancer fields to disease areas such as multiple sclerosis. Unfortunately, there is no current proven general treatment of prevention strategy for nucleoside drug-..
  34. Astrocytes Play a Critical Role in the Pathology of EAE
    JOHN ROLAND BETHEA; Fiscal Year: 2013
    Project Summary Multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) are believed to be initiated by T cell-mediated immune responses to myelin antigens...
  35. Novel Functions of S1P in Neuroinflammation
    TOMASZ K KORDULA; Fiscal Year: 2013
    ..Interleukin 1 (IL-1) is a proinflammatory cytokine that is critical for the development and progression of multiple sclerosis (MS) in humans and experimental autoimmune encephalomyelitis (EAE) in mice...
  36. MOLECULAR MIMICRY IN IMMUNE MEDIATED NEUROLOGIC DISEASE
    Michael Levin; Fiscal Year: 2013
    ..is to elucidate novel mechanisms of neurodegeneration related to the pathogenesis of progressive forms of multiple sclerosis (MS), a common cause of disability in United States Veterans...
  37. Sex Differences and Estrogen Receptors Regulate Dendritic Cells in Inflammation
    Susan Kovats; Fiscal Year: 2010
    ..REGULATE DENDRITIC CELLS IN INFLAMMATION Abstract Autoimmune diseases such as rheumatoid arthritis and multiple sclerosis are strongly female biased, yet the cellular and molecular basis for this is not understood...
  38. High Throughput Screening of the Autoimmune Epitome
    Nancy J Olsen; Fiscal Year: 2010
    ..affected by an autoimmune disorder such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), or multiple sclerosis (MS)...
  39. Neuroimmune modulation across the BBB: Regulation of ILS trafficking by TNF
    Weihong Pan; Fiscal Year: 2012
    ..experimental autoimmune encephalomyelitis (EAE), a disorder of neuroimmune modulation and a model for multiple sclerosis. The regulatory changes of IL15 permeation across the BBB of the EAE mice will be determined, and the ..
  40. PROTEIN CARBONYLATION AND AXONAL DAMAGE IN EAE
    Oscar A Bizzozero; Fiscal Year: 2012
    Our long-term goal is to define and characterize the mechanisms underlying tissue injury in multiple sclerosis, the most common demyelinating disease of the central nervous system in humans...
  41. Define the role of dendritic cells in HTLV-1 associated neuroinflammatory disease
    Pooja Jain; Fiscal Year: 2013
    ..disease with underlying autoimmune condition in the central nervous system with similarities to multiple sclerosis. The progression of HAM/TSP is characterized by an intense proliferation of chronically activated CD8+ ..
  42. New Peptides for the Treatment of Multiple Sclerosis
    Christine Beeton; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that leads to severe disability and death...
  43. A Systems Biology Approach for Pediatric and Adult Autoimmune Diseases
    MARIA VIRGINIA PASCUAL; Fiscal Year: 2013
    ..2) Development of biomarkers for dermatomyositis, psoriasis, lupus and multiple sclerosis. 3) Identification of novel therapeutic targets in dermatomyositis...
  44. Advanced Magnetization Transfer Imaging in Multiple Sclerosis Disease
    Alexey Samsonov; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Advanced Quantitative Magnetization Transfer Imaging in Multiple Sclerosis Disease Multiple sclerosis (MS) is a complex neurodegenerative disease that is highly variable in symptoms, clinical course, ..
  45. Experimental Optic Neuritis: Gene Therapy
    John Guy; Fiscal Year: 2011
    ..have a protective effect on suppressing experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis (MS)...
  46. Immune Regulation of CNS Viral Recrudescence
    Cornelia Bergmann; Fiscal Year: 2010
    ..in humans during infections associated with neurological complications and the demyelinating disease multiple sclerosis (MS)...
  47. SEX EFFECTS ON CHEMOKINE MEDIATED CNS AUTOIMMUNITY
    Lillian Cruz-Orengo; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Multiple Sclerosis (MS) in the most common inflamatory disease of the nervous system, manifested by attacks of muscle weakness and loss of coordination, visual disturbances, bladder dysfunction and ..
  48. Identification of stromal responses during castration-induced thymic regrowth.
    Howard T Petrie; Fiscal Year: 2013
    ..for diseases like leukemia, and an emerging therapy for autoimmune disorders like lupus erythematosus and multiple sclerosis. Correcting and/or preventing age-related thymic degeneration (atrophy) is thus of substantial importance ..
  49. Freeze-Dried Blueberries: Prevention and Rehabilitation Strategies in MS
    Susan O McGuire; Fiscal Year: 2011
    ..cost alternative and/or adjuvant treatment to improve the care of veterans suffering from service-connected Multiple Sclerosis (MS)...
  50. Murine coronavirus neurovirulence: role of type I interferon response
    Susan R Weiss; Fiscal Year: 2013
    ..and compelling model for studying virus-induced encephalitis and chronic demyelinating diseases such as multiple sclerosis (MS)...
  51. Neurorestorative Strategy for Diabetic Peripheral Neuropathy
    Feng Qiao Li; Fiscal Year: 2013
    ..of neurological disorders such as traumatic brain injury, spinal cord injury, subarachnoid hemorrhage and multiple sclerosis, implicating a therapeutic efficacy for these diseases...
  52. Viral suppression of CNS autoimmunity
    Stephen A Stohlman; Fiscal Year: 2013
    ..infection of the central nervous system (CNS) that induces significant demyelination, a hallmark of human multiple sclerosis (MS) and murine experimental autoimmune encephalitis (EAE), without progressing to autoimmunity...
  53. Regulation of B cells in the CNS
    Cornelia Bergmann; Fiscal Year: 2013
    ..B cells within the central nervous system (CNS) is well documented in humans with the demyelinating disease multiple sclerosis (MS) and those afflicted by neurotropic infections. Their role in MS is currently unclear...
  54. AUTOIMMUNITY CENTER OF EXCELLENCE
    David Wofsy; Fiscal Year: 2013
    ..This proposal focuses primarily on three of these diseases (systemic lupus erythematosus, multiple sclerosis, and type 1 diabetes mellitus), but we also describe active programs in several other autoimmune diseases, ..
  55. Investigating the mechanism of TNFalpha mediated cell death in oligodendrocytes
    Junying Yuan; Fiscal Year: 2013
    ..of this pathway to progressive demyelination, inflammation and neurodegeneration in animal models of multiple sclerosis (MS)...
  56. T CELL RESPONSE TO MYELIN PROTEOLIPID PROTEIN
    Vijay K Kuchroo; Fiscal Year: 2013
    ..encephalomyelitis (EAE) is an animal model that reproduces many of the clinical and pathological features of multiple sclerosis (MS)...
  57. Antibody Mediated Autoimmunity in Neuromyelitis Optica
    HANS CHRISTIAN VON BUEDINGEN; Fiscal Year: 2013
    ..demyelinating disorders of the central nervous system (CNS) such as neuromyelitis optica (NMO) and multiple sclerosis (MS). NMO is a severe inflammatory demyelinating disease affecting the optic nerves and spinal cord...
  58. Novel functions of RGS3
    Nickolai O Dulin; Fiscal Year: 2012
    ..immunity, whereas abnormal function of T cells leads to autoimmune and inflammatory diseases such as asthma, multiple sclerosis, rheumatoid arthritis, type I diabetes and others...
  59. GSK3: immunoregulator in experimental autoimmune encephalomyelitis (EAE)
    Patrizia De Sarno; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS), characterized by an immune-mediated demyelination and neurodegeneration of the CNS, for which there ..
  60. CD-73 adenosine signaling in the central nervous system in disease and health
    Margaret S Bynoe; Fiscal Year: 2012
    b>Multiple Sclerosis (MS) is an inflammatory attack on the central nervous system (CNS) that results in loss of neuronal function and can lead to death...
  61. Mechanism of SIRT1 activator mediated neuroprotection of retinal ganglion cells
    Kenneth S Shindler; Fiscal Year: 2013
    ..of the optic nerve that occurs in association with the central nervous system (CNS) demyelinating disease multiple sclerosis (MS) and leads to permanent visual loss in up to 40% of patients...
  62. Innate Regulation and CD4+Th1/17 Immunity in TMEV-Induced Demyelination
    Stephen D Miller; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Multiple sclerosis (MS) is an autoimmune paralytic disease caused by immune cell-mediated destruction of myelin-producing ..
  63. Bladder Voiding via Pudendal Nerve Block
    KENNETH GUSTAFSON; Fiscal Year: 2009
    ..dysfunction after neurological injury or disorders such as spinal cord injury (SCI), brainstem stroke, and multiple sclerosis can have a devastating impact on patients and their families, resulting in a high cost to the individual and ..
  64. Long Acting Beta Interferon for Treating Multiple Sclerosis - Phase II Continuing
    George Cox; Fiscal Year: 2009
    ..human beta interferon products have annual worldwide sales of $4 billion, primarily from their use to treat Multiple Sclerosis. Beta interferon has a short half-life in humans, which necessitates frequent dosing and may not optimize ..
  65. DEMYELINATING DISEASE: VIRAL AND IMMUNE FUNCTION
    Stephen Stohlman; Fiscal Year: 2007
    ..infectious virus is associated with chronic ongoing myelin loss, which has numerous similarities to multiple sclerosis, the most prevalent human demyelinating disease...
  66. MYELIN BASIC PROTEIN PEPTIDES IN BODY FLUIDS
    JOHN WHITAKER; Fiscal Year: 1993
    ..from damaged central nervous system myelin enter cerebrospinal fluid, blood and urine of persons with multiple sclerosis and that measurement of these peptides offers a means of monitoring of tissue injury...
  67. MULTIPLE-SCLEROSIS: A CD40 LIGAND ANTAGONIST
    Lloyd Kasper; Fiscal Year: 2003
    b>Multiple sclerosis (MS) is a clinical neurological disease characterized by chronic inflammation, demyelination and gliosis of the central nervous system...
  68. MULTIPLE-SCLEROSIS: A CD40 LIGAND ANTAGONIST
    Lloyd Kasper; Fiscal Year: 2005
    b>Multiple sclerosis (MS) is a clinical neurological disease characterized by chronic inflammation, demyelination and gliosis of the central nervous system...
  69. Development of a T cell specific multiple sclerosis drug
    Arthur Vandenbark; Fiscal Year: 2005
    The broad, long-term objective of this project is to develop a new class of drugs for treatment of multiple sclerosis (MS)...
  70. Beta-lactam chemical probes for GLT-1 transporter-related pathologies
    Scott M Rawls; Fiscal Year: 2010
    ..neurological and pathological disorders, including such as epilepsy, stroke, amyotrophic lateral sclerosis, multiple sclerosis, depression and addiction (Rothstein et al., 2005)...
  71. Neuroimaging of MS - State of the Art and Future Directions
    Oded Gonen; Fiscal Year: 2009
    ..The target audience is interdisciplinary: PhD and MD (radiology and neurology) experts in the fields of multiple sclerosis (MS) imaging and management...
  72. Mining the Multiple Sclerosis miRNome for Disease Markers
    Amy E Lovett Racke; Fiscal Year: 2010
    b>Multiple sclerosis (MS) is the most prevalent, demyelinating disease of the central nervous system (CNS), causing progressive physical and cognitive disability...
  73. DNA-Based Biomarkers for Multiple Sclerosis
    Victor Levenson; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is a chronic, inflammatory neurodegenerative disease that affects the central nervous system and may lead to severe disability within 10-15 years...
  74. OLFACTION IN MULTIPLE SCLEROSIS
    RICHARD DOTY; Fiscal Year: 2001
    DESCRIPTION (Adapted from the Investigator's Abstract): Multiple sclerosis (MS) can lead to paralysis and death and affects millions of Americans, often in the prime of their lives...
  75. OPTIC NERVE DEMYELINATION STUDY USING MRI
    Scott Fraser; Fiscal Year: 2001
    DESCRIPTION: (Verbatim from the Applicant's Abstract) Although the symptomology of multiple sclerosis (MS) has been described for decades, an understanding of the mechanisms and causes of the disease are only now emerging...
  76. EPIGALLOCATECHIN GALLATE AS A NEUROPROTECTANT IN A MODEL OF MULTIPLE SCLEROSIS
    Gail Marracci; Fiscal Year: 2007
    ..EGCG is a potent inhibitor of experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. The specific aims of this proposal seek to provide the pre-clinical data needed to design clinical trials ..
  77. DIETARY ETIOLOGIES OF MULTIPLE SCLEROSIS AND PARKINSONS
    Alberto Ascherio; Fiscal Year: 2001
    We propose to document the occurrence of multiple sclerosis (MS) and Parkinson's disease (PD) among male and female participants of three large ongoing prospective studies and to examine prospectively the association between several ..
  78. A novel splice variant of interleukin-13 and its role in promoting EAE responses
    Michael K Shaw; Fiscal Year: 2010
    ..phase of EAE? Specific Aim 3: Do B cells augment EAE solely by secreting IL-13 E2? Public Health Relevance: Multiple sclerosis is a human autoimmune disease which afflicts more than 400,000 Americans...
  79. Novel therapy for treating Multiple Sclerosis
    KENNETH PILLER; Fiscal Year: 2009
    A variety of therapies have been attempted to treat Multiple Sclerosis. Such experimental therapies have included the administration of myelin basic protein, administration of peptides derived from myelin basic protein, injection of the ..
  80. Drug Repurposing using Pharmacological Networks
    MICHAEL JAMES KEISER; Fiscal Year: 2010
    ..The specific aims are: Aim 1. To predict and test established drugs that act on targets in the areas of Multiple Sclerosis and cardiovascular disease. a...